rsv arexvy - Search News

News

GSK, RSV and EMA

EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,

· 3d · on MSN

GSK applies to EU regulator for expanded use of RSV vaccine

Medical Dialogues · 2d

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

33m

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...

STAT4d

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

GSK, RSV and EMA

Trending now